POREMEĆAJI FUNKCIJE ŠTITASTE ŽLEZDE KOD PACIJENATA SA HRONIČNOM OPSTRUKTIVNOM BOLEŠĆU PLUĆA

Dusica Brkic

doi:10.5937/mckg49-7025

Dusica Brkic Dom zdravlja Kragujevac, Zdravstvena stanica 1

DOI: https://doi.org/10.5937/mckg49-7025

Abstract

Hronična opstruktivna bolest pluća (HOBP) je respiratorni poremećaj u kome postoji hronično ograničenje protoka vazduha kroz disajne puteve. Hronični bronhitis i emfizem predstavljaju glavne komponente HOBP. Faktori rizika za razvoj bolesti obuhvataju faktore spoljašnje sredine (izloženost štetnim česticama i gasovima) i faktore domaćina. HOBP je jedan od vodećih uzroka morbiditeta i mortaliteta širom sveta. U okviru bolesti javljaju se brojni ekstrapulmonalni efekti, uključujući i poremećaje funkcijе štitaste žlezde. Pretpostavljeni mehanizmi odgovorni za disfunkciju štitaste žlezde odnose se na opstrukciju disajnih puteva, hipoksemiju, sistemsku inflamaciju i efekat glukokortikoida. Poremećaj funkcije štitaste žlezde, prezentovan kao hipertireoidizam ili hipotireoidizam, najčešće je diskretan i biva intenziviran u fazama egzacerbacije bolesti. Svojim prisustvom indukuje dodatna oštećenja i povećava rizik za nastanak respiratorne insuficijencije.

Ključne reči: hronična opstruktivna bolest pluća, ekstrapulmonalni efekti, tireoidna funkcija

References

Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease. 2008. www.goldcopd.org Date last updated: January 2009. Date last accessed: July 2, 2009.

Siafakas NM. Definition and differential diagnosis of chronic obstructive pulmonary disease. In: Siafakas NM, ed. Management of Chronic Obstructive Pulmonary Disease. Eur Respir Mon 2006; 38: 1-6.

Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management,and prevention of chronic obstructive pulmonary disease. Risk Factors. NHLBI/ WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 20-5.

Cerveri I, Brusasco V. Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur Respir Rev 2010; 19: 109-112.

Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8.

Gold DR, Wang X, Wypij D. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-7.

Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991; 144: 17-22.

Sandford AJ, Weir TD, Paré PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1380-91.

Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res 2001; 2: 20-6.

Celli B R. Update on the managment of COPD. Chest 2008; 133: 1451-62.

Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.

Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412.

Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.

Agusti AG, Sauleda J, Miralles C. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485-9.

Sin DD, Man SF. Why are patients with chroni obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-9.

Debigare R, Marquis K, Cote CH. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124: 83-9.

Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J 2009; 34: 975-996.

Karadag F, Ozcan H, Karul AB, Yilmaz M, Cildaq O. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med 2007; 101: 1439-1446.

Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 2001; 50: 1397-1401.

Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 76-80.

Verleden GM, Demedts MG, Westhovens R, Thomeer M. Pulmonary manifestations of systemic diseases. Eur Respir Monogr 2006; 34: 234-252.

Magd MG, Sabah SO, Manal AH, Taghreed SF, Rayyah AS, Heba HE. Pulmonary function tests and thyroid hormone level in patients with chronic obstructive pulmonary disease. Egypt J Chest 2011; 60: 87-92.

Uzun K, Atalay H, Inal A. Thyroid hormone levels in patients with acute exacerbation of chronic obstructive pulmonary disease. Eur J Gen Med 2007; 4: 80-88.

Jack AE. Changes in chronic obstructive pulmonary disease patients with a preliminary study of thyroid function. Metabolism 2012; 150: 1397-1401.

Gow SM, Seth J, Beckett GJ, Douglas G. Thyroid function and endocrine abnormalities in elderly patients with severe chronic obstructive lung disease. Thorax 1987; 42: 520-5.

Ulasli SS, Bozbas SS, Ozen ZE, Ozyurek BA, Ulubay G. Effect of thyroid function on COPD exacerbation frequency: a preliminary study. Multidiscip Respir Med 2013; 8: 64.

Wiersinga WM. Nonthyroidal illness. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 247-263.

Rubello D, Sonino N, Casara D, Girelli M, Busnardo B, Boscaro M. Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. J Endocrinol Invest 1992; 15: 437-441.

LoPresti JS, Eigen A, Kaptein E, Anderson KP, Nicoloff JT. Alterations in 3,3959-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. J Clin Invest 1989; 84: 1650-1656.

Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,39,59-triiodothyronine (reverse T3) and 3,395-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41: 911-920.

Wouters EF, Schols MW, Celli B. Systemic effects of chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 224-241.

Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167: 1428-1432.

Pino-Garcia JM, Garcia-Rio F, Diez JJ, et al. Regulation of breathing in hyperthyroidism: relationship to hormonal and metabolic changes. Eur Respir J 1998; 12: 400-407.

Ingbar DH. The pulmonary system in hypothyroidism. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 781-788.

Kahaly GJ, Nieswandt J, Wagner S, Schlegel J, Mohr-Kahaly S, Hommel G. Ineffective cardiorespiratory function in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 4075-4078.

Laroche CM, Cairns T, Moxham J, Green M. Hypothyroidism presenting with respiratory muscle weakness. Am Rev Respir Dis 1988; 138: 472-474.

Pelttari L, Rauhala E, Polo O, et al. Upper airway obstruction in hypothyroidism. J Intern Med 1994; 236: 177-181.

Banks WA, Cooper JA. Hypoxia and hypercarbia of chronic lung disease: Minimal effects on anterior pituitary function. South Med J 1990; 83: 290-293.

Abo El-Yazed HA, El-Bassiony MR, Eldaboosy SM, El Gendi AE, Hashim M. Assessment of thyroid functions in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuber 2013; 62: 387-391.